Patents Represented by Attorney Susan T. Evans
  • Patent number: 6194542
    Abstract: The present invention provides methods and compositions relating to cytomegalovirus (CMV) latent transcripts, latency-associated polypeptides and antibodies directed against such polypeptide. The polypeptides are encoded by CMV DNA sequences and are produced specifically during latent infection. Also provided are methods of detecting CMV in a sample, particularly CMV in a latent state. The methods include RT-PCR-based methods and immunodiagnostic methods.
    Type: Grant
    Filed: November 21, 1997
    Date of Patent: February 27, 2001
    Assignee: The Board of Trustees of the Leland Stanford Junior University
    Inventors: Kazuhiro Kondo, Edward S. Mocarski, Jr.
  • Patent number: 6187344
    Abstract: Dispersibility of a respirable powder, administrable by inhalation, is increased by including a pharmaceutically acceptable water-soluble polypeptide.
    Type: Grant
    Filed: July 31, 1997
    Date of Patent: February 13, 2001
    Assignee: Inhale Therapeutic Systems
    Inventors: Mohammed Eljamal, John S. Patton, Linda C. Foster, Robert M. Platz
  • Patent number: 6136346
    Abstract: Dispersibility of a respirable powder, administrable by inhalation, is increased by including a pharmaceutically acceptable water-soluble polypeptide.
    Type: Grant
    Filed: March 17, 1998
    Date of Patent: October 24, 2000
    Assignee: Inhale Therapeutic Systems
    Inventors: Mohammad Eljamal, John S. Patton, Linda Foster, Robert M. Platz
  • Patent number: 6123936
    Abstract: According to the present invention, methods and compositions are provided for spray-dried, interferon-based dry powder compositions, particularly interferon-beta. The compositions are useful for treating conditions in humans that are responsive to treatment with interferons. In particular, the methods of the present invention rely on spray drying to produce stable, high-potency dry powder formulations of interferons, including but not limited to IFN-beta. Surprisingly, it has been found that IFN can be prepared in high potency, dry powder formulations by spray drying. Such dry powder formulations find particular utility in the pulmonary delivery of IFN.
    Type: Grant
    Filed: November 22, 1999
    Date of Patent: September 26, 2000
    Assignee: Inhale Therapeutics Systems, Inc.
    Inventors: Robert M. Platz, Shigenobu Kimura, Yu-ichiro Satoh, Linda C. Foster
  • Patent number: 6103875
    Abstract: The present invention is directed to a family of unique antimycotic lipopeptide compounds produced by Pseudomonas viridiflava. The lipopeptides are effective against both human and plant fungal pathogens, and are typically characterized by their ability to inhibit growth of Candida albicans. Representative lipopeptides of the invention have molecular weights of 1137, 1153, 1164 and 1181 daltons.
    Type: Grant
    Filed: November 26, 1997
    Date of Patent: August 15, 2000
    Assignee: Pharmagenesis, Inc.
    Inventors: Concepcion Martinez-Miller, Roger V. Miller, Gary A. Strobel
  • Patent number: 6071428
    Abstract: In a composition which has an amorphous, undercooled, glassy phase containing a water-soluble or water-swellable substance in an amorphous form, a sugar, which is capable of existing as a crystalline hydrate, is used as an agent to dehydrate the amorphous phase by crystallization therefrom, and thereby enhance the glass transition temperature of the residual amorphous phase.
    Type: Grant
    Filed: April 26, 1996
    Date of Patent: June 6, 2000
    Assignee: Inhale Therapeutic Systems
    Inventors: Felix Franks, Barry Aldous, Anthony Auffret
  • Patent number: 6054635
    Abstract: The present invention is directed to the identification and isolation of a promoter region from a raspberry genome. The promoter is operably linked, in a native raspberry genome, to the coding region of a raspberry E4 gene. The raspberry E4 gene promoter of the invention is capable of regulating moderate level, constitutive expression of a heterologous plant gene under its control. The invention is further directed to chimeric genes, cassette vectors, kits, transgenic plants, and methods employing a raspberry E4 promoter.
    Type: Grant
    Filed: December 27, 1996
    Date of Patent: April 25, 2000
    Assignee: Agritope, Inc.
    Inventors: Richard K. Bestwick, Jill A. Kellogg, Helena V. Mathews
  • Patent number: 5939096
    Abstract: A method of stably encapsulating a weak acid drug in liposomes, at a high concentration, is disclosed. The method employs a proton shuttle mechanism involving the salt of a weak acid to generate a higher inside/lower outside pH gradient. The weak acid compound accumulates in liposomes in response to this gradient, and may be retained in the liposomes by cation-promoted precipitation or low permeability across the liposome transmembrane barrier. Also disclosed is a reagent combination for practicing the method, and a liposome composition formed by the method.
    Type: Grant
    Filed: May 29, 1997
    Date of Patent: August 17, 1999
    Assignee: Yissum Research Development Company of the Hebrew University of Jerusalem
    Inventors: Stephane Clerc, Yechezkel Barenholz
  • Patent number: 5874563
    Abstract: Polypeptide antigens are disclosed which are immunoreactive with sera from individuals having a non-A, non-B, non-C, non-D, non-E Hepatitis, herein designated Hepatitis G Virus (HGV). Corresponding genomic-fragment clones containing polynucleotides encoding the open reading frame sequences for the antigenic polypeptides are taught. The antigens are useful in diagnostic methods for detecting the presence of HGV in test subjects. The antigens are also useful in vaccine and antibody preparations. In addition, the entire coding sequences of two HGV isolates are disclosed. Methods are presented for nucleic acid-based detection of HGV in samples and also methods for the isolation of further genomic sequences corresponding to HGV.
    Type: Grant
    Filed: June 5, 1995
    Date of Patent: February 23, 1999
    Assignee: Genelabs Technologies, Inc.
    Inventors: Jungsuh P. Kim, Kirk E. Fry, Lavonne Marie Young, Jeffrey M. Linnen, John Wages
  • Patent number: 5859330
    Abstract: The present invention relates to chimeric genes having (i) a DNA sequence encoding a product that is effective to reduce ethylene biosynthesis in fruit from the plant, and (ii) a promoter whose expression is induced during fruit ripening or by ethylene synthesis by the fruit, where the DNA sequence is heterologous to the promoter and the DNA sequence is operably linked to the promoter to enable expression of the product. The invention describes vectors and transgenic plants, vegetables, flowers and fruits carrying the chimeric gene, as well as methods related thereto.
    Type: Grant
    Filed: October 27, 1994
    Date of Patent: January 12, 1999
    Assignee: Epitope, Inc.
    Inventors: Richard Keith Bestwick, Adolph J. Ferro
  • Patent number: 5859230
    Abstract: Polypeptide antigens are disclosed which are immunoreactive with sera from individuals infected with non-A, non-B, non-C, non-D, non-E hepatitis. Also disclosed are corresponding genomic-fragment clones containing polynucleotides encoding the open reading frame sequences for the antigenic polypeptides. The antigens are useful in diagnostic methods for detecting the presence of N-(ABCDE) hepatitis agent infection in primates. The antigens are also useful in vaccine and antibody preparations. Methods are presented for the isolation of entire genomes corresponding to the N-(ABCDE) hepatitis agents.
    Type: Grant
    Filed: March 6, 1996
    Date of Patent: January 12, 1999
    Assignee: Genelabs Technologies, Inc.
    Inventors: Jungsuh P. Kim, Gregory R. Reyes, LaVonne Marie Young
  • Patent number: 5856134
    Abstract: Polypeptide antigens are disclosed which are immunoreactive with sera from individuals having a non-A, non-B, non-C, non-D, non-E Hepatitis, herein designated Hepatitis G Virus (HGV). Corresponding genomic-fragment clones containing polynucleotides encoding the open reading frame sequences for the antigenic polypeptides are taught. The antigens are useful in diagnostic methods for detecting the presence of HGV in test subjects. The antigens are also useful in vaccine and antibody preparations. In addition, the entire coding sequences of two HGV isolates are disclosed. Methods are presented for nucleic acid-based detection of HGV in samples and also methods for the isolation of further genomic sequences corresponding to HGV.
    Type: Grant
    Filed: June 5, 1995
    Date of Patent: January 5, 1999
    Assignee: Genelabs Technologies, Inc.
    Inventors: Jungsuh P. Kim, Kirk E. Fry, LaVonne Marie Young, Jeffrey M. Linnen, John Wages
  • Patent number: 5849532
    Abstract: Polypeptide antigens are disclosed which are immunoreactive with sera from individuals having a non-A, non-B, non-C, non-D, non-E Hepatitis, herein designated Hepatitis G Virus (HGV). Corresponding genomic-fragment clones containing polynucleotides encoding the open reading frame sequences for the antigenic polypeptides are taught. The antigens are useful in diagnostic methods for detecting the presence of HGV in test subjects. The antigens are also useful in vaccine and antibody preparations. In addition, the entire coding sequences of two HGV isolates are disclosed. Methods are presented for nucleic acid-based detection of HGV in samples and also methods for the isolation of further genomic sequences corresponding to HGV.
    Type: Grant
    Filed: June 6, 1995
    Date of Patent: December 15, 1998
    Assignee: Genelabs Technologies, Inc.
    Inventors: Jungsuh P. Kim, Kirk E. Fry, LaVonne Marie Young, Jeffrey M. Linnen, John Wages
  • Patent number: 5830655
    Abstract: The present invention provides modified oligonucleotide primers designed to incorporate a cleavable moiety so that a 3' portion of the primer (linked to an extension product) can be released from an upstream 5' portion of the primer. Upon selective cleavage of the cleavable site, primer extension products that contain about five or fewer base pairs of the primer sequence are released, to provide more useful sizing and sequence information per fragment than extension products containing the entire primer.
    Type: Grant
    Filed: April 26, 1996
    Date of Patent: November 3, 1998
    Assignee: SRI International
    Inventors: Joseph Albert Monforte, Christopher Hank Becker, Thomas Andrew Shaler, Daniel Joseph Pollart
  • Patent number: 5824507
    Abstract: Polypeptide antigens are disclosed which are immunoreactive with sera from individuals having a non-A, non-B, non-C, non-D, non-E Hepatitis, herein designated Hepatitis G Virus (HGV). Corresponding genomic-fragment clones containing polynucleotides encoding the open reading frame sequences for the antigenic polypeptides are taught. The antigens are useful in diagnostic methods for detecting the presence of HGV in test subjects. The antigens are also useful in vaccine and antibody preparations. In addition, the entire coding sequences of two HGV isolates are disclosed. Methods are presented for nucleic acid-based detection of HGV in samples and also methods for the isolation of further genomic sequences corresponding to HGV.
    Type: Grant
    Filed: May 19, 1995
    Date of Patent: October 20, 1998
    Assignee: Genelabs Technologies, Inc.
    Inventors: Jungsuh P. Kim, Kirk E. Fry, LaVonne Marie Young, Jeffrey M. Linnen, John Wages
  • Patent number: 5795976
    Abstract: The present invention describes a method for separating heteroduplex and homoduplex DNA molecules in a mixture. In the method, such a mixture is applied to a stationary reverse phase support. The heteroduplex and homoduplex molecules are eluted with a mobile phase containing an ion-pairing reagent and an organic solvent. The eluting is carried out under conditions effective to at least partially denature the heteroduplexes (e.g., thermal or chemical denaturing) resulting in the separation of the heteroduplexes from the homoduplexes. The method has many applications including, but not limited to, comparative nucleic acid sequencing, linkage analysis, evolutionary studies, forensics, identification of disease-causing gene mutations, genetic marker development and diagnostics.
    Type: Grant
    Filed: August 8, 1995
    Date of Patent: August 18, 1998
    Assignee: The Board of Trustees of the Leland Stanford Junior University
    Inventors: Peter Josef Oefner, Peter Anton Underhill
  • Patent number: 5789431
    Abstract: The invention provides 1,4-naphthoquinone compounds and a method for inhibiting tumor cell growth in a subject by administering such compounds. The compounds are represented by the structures: ##STR1## where R.sub.1 is lower alkyl, halogenated lower alkyl, phenyl, benzyl, phenethyl, or --(CH.sub.2).sub.m COOX where m is 2 or 3 and X is H, methyl, or ethyl; R.sub.2 is halo or NHY, where Y is hydrogen, lower alkyl, halogenated lower alkyl, hydroxylated lower alkyl, lower dialkylaminoalkyl, phenyl, benzyl, or phenethyl; R.sub.3 is lower alkyl, halogenated lower alkyl, phenyl, benzyl, phenethyl, or --(CH.sub.2).sub.m COOX, where m and X are as defined for R.sub.1 above; and R.sub.4 is hydrogen, lower alkyl, lower aminoalkyl, halogenated lower alkyl, phenyl, benzyl, or phenethyl.
    Type: Grant
    Filed: February 16, 1996
    Date of Patent: August 4, 1998
    Assignee: The University of North Carolina at Chapel Hill
    Inventors: Kuo-Hsiung Lee, Sheng-Chu Kuo, Toshiro Ibuka
  • Patent number: 5783393
    Abstract: The present invention relates to chimeric genes having (i) a DNA sequence encoding a product of interest, and (ii) a dru1 promoter, where said DNA sequence is heterologous to said promoter and said DNA sequence is operably linked to said promoter to enable expression of said product. The invention describes vectors, cells, plants, and fruits carrying the chimeric gene, as well as methods related thereto.
    Type: Grant
    Filed: January 29, 1996
    Date of Patent: July 21, 1998
    Assignee: Agritope, Inc.
    Inventors: Jill Anne Kellogg, Richard Keith Bestwick
  • Patent number: 5783394
    Abstract: The present invention is directed to the identification and isolation of two different promoter regions from the raspberry genome. The promoter regions are operably linked, in a native raspberry genome, to the coding region of a raspberry dru1 gene. Promoters of the invention are capable of regulating moderate level, constitutive expression of heterologous plant genes under their control. The invention is further directed to chimeric genes, cassette vectors, kits, transgenic plants, and methods employing such promoters.
    Type: Grant
    Filed: January 24, 1997
    Date of Patent: July 21, 1998
    Assignee: Agritope, Inc.
    Inventors: Richard K. Bestwick, Jill Anne Kellogg
  • Patent number: 5766916
    Abstract: The protease necessary for polyprotein processing in Hepatitis G virus (HGV) is identified, cloned, and expressed. Proteases, truncated protease, and altered proteases are disclosed which are useful for cleavage of specific polypeptides, and for assay and design of antiviral agents specific for HGV.
    Type: Grant
    Filed: April 24, 1996
    Date of Patent: June 16, 1998
    Assignee: Genelabs Technologies, Inc.
    Inventors: Alexander S. Belyaev, Susan M. Chong